Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-6628 in Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Oct 2029
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of abbv-6628 in geographic atrophy (GA), sponsored by AbbVie Inc.. Started Aug 2025; status: recruiting.
02
Drugs
abbv-6628
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07160179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160179.